Abstract

Radiofrequency Echographic Multi Spectrometry (REMS) is a non-invasive, radiation-free diagnostic tool for assessing bone mineral density (BMD). It is especially useful for the diagnosis and monitoring of osteoporosis, focusing on the lumbar spine and femoral neck regions. Compared to conventional dual-energy X-ray absorptiometry (DXA), REMS offers a portable and efficient alternative that allows for more frequent and accessible BMD measurements, including for patients in underserved populations, such as pregnant women and individuals with limited mobility. The current evidence supports the use of REMS as a useful tool in the management of osteoporosis, offering advantages such as reducing the impact of calcification-related artifacts and facilitating bone quality assessment with its proprietary Fragility Score. This narrative review delves into the clinical applications of REMS, its mechanisms, and its effectiveness in predicting fractures, with a particular focus on its potential as an alternative or complement to DXA in clinical practice.

Introduction

Osteoporosis is a condition characterized by a decrease in bone mass and microarchitectural deterioration, leading to an increased risk of fragility fractures. It is prevalent globally, affecting over 200 million people, with one in two women and one in five men over the age of 50 years experiencing a fragility fracture in their lifetime. Diagnosing osteoporosis is challenging as it remains asymptomatic until a fracture occurs, making the assessment of fracture risk and BMD crucial for both diagnosis and treatment decisions.

Dual-energy X-ray absorptiometry (DXA) has been the standard method for measuring BMD at axial reference sites, such as the lumbar spine and femoral neck. However, despite its widespread use, DXA has limitations, including the use of ionizing radiation, low portability, and limited availability in certain settings. Other imaging modalities, such as quantitative computed tomography (QCT), high-resolution peripheral QCT (HR-pQCT), and magnetic resonance imaging (MRI), are primarily used in research and have their own set of limitations, including high costs, operator dependence, and access challenges.

Radiofrequency Echographic Multi Spectrometry (REMS) offers an innovative solution to these challenges. REMS uses ultrasound technology to assess bone quality and measure BMD at critical skeletal sites, such as the lumbar spine and femoral neck, without exposing patients to ionizing radiation. Its portability, rapid acquisition times, and absence of ionizing radiation make it an attractive option, particularly for populations such as pregnant women, the elderly, and those with limited access to conventional BMD assessment methods.

How Does REMS Work?

REMS employs ultrasound technology to assess bone health by capturing back-scattered waveforms from bone interfaces. A transducer emits ultrasound at the target site, and the resulting signals are analyzed using B-mode image reconstruction to produce detailed images of the region of interest. The analysis is enhanced by advanced spectral processing algorithms that identify bone structures and evaluate the internal microarchitecture of the bone.

One of the key advantages of REMS is its ability to automatically adjust for artifacts caused by calcifications, osteophytes, metal implants, or vertebral fractures, which can distort DXA measurements. This feature ensures more accurate assessments of BMD, particularly in patients with conditions that commonly introduce such artifacts.

Unlike DXA, REMS also provides a Fragility Score, which quantifies bone quality by analyzing the bone’s microarchitecture and its correlation with fracture risk. The Fragility Score is a crucial component of REMS, as it offers a more comprehensive evaluation of bone health beyond simple BMD measurement.

Basic Principles of REMS

• (a) Lumbar spine REMS scan.
• (b) Simultaneous acquisition of native raw unfiltered signals.
• (c) Spectral processing of acquired signals.
• (d) Comparison of patient spectra with reference models.

This approach is particularly beneficial for diagnosing osteoporosis, predicting fractures, and monitoring therapeutic interventions.

Clinical Applications and Advantages of REMS

REMS offers significant advantages over traditional DXA in various clinical settings:

• Portability and Accessibility: REMS is portable and does not require the bulky equipment of DXA machines. This makes it feasible for use in primary care, emergency departments, and even at home. The ability to perform REMS at the bedside is particularly valuable for frail patients who may find it challenging to visit a clinic for DXA scans.
• Non-Ionizing Radiation: Unlike DXA, which uses ionizing radiation, REMS is a radiation-free technology. This makes it an ideal option for vulnerable populations, such as pregnant women, children, and individuals requiring frequent BMD monitoring. The absence of radiation also reduces the long-term risks associated with repeated imaging.
• Artifact-Free Imaging: REMS is highly effective at eliminating the influence of common artifacts, such as calcifications or metal implants, which often interfere with DXA measurements. This makes REMS particularly advantageous for patients with conditions like osteoarthritis, cardiovascular diseases, or those with metal prosthetics.
• Bone Quality Assessment: In addition to providing BMD measurements, REMS also assesses bone quality through the Fragility Score. This score offers additional information that is independent of BMD and is specifically designed to predict fracture risk, thus providing a more comprehensive evaluation of bone health.

The REMS Fragility Score

The REMS Fragility Score is a key metric used to assess the risk of future fractures. It is calculated by analyzing the bone microarchitecture and comparing it with a spectral model derived from a population of both healthy and osteoporotic individuals. The Fragility Score ranges from 0 (indicating normal bone health) to 100 (indicating maximum fragility).

This score has been validated in multiple studies and has demonstrated strong predictive value for fractures. For instance, a five-year follow-up study confirmed that the Fragility Score significantly outperformed traditional BMD measurements in predicting fragility fractures. As a result, the Fragility Score has become an essential component of fracture risk assessment in clinical practice.

Example of a REMS Diagnostic Report
This report provides a comprehensive view of the BMD and bone quality at the lumbar spine and femoral neck, highlighting key metrics such as T-scores, Z-scores, and the Fragility Score.

REMS in Specific Populations

Pregnancy

REMS offers a safe and effective means of monitoring bone health during pregnancy. Since it does not use ionizing radiation, it can be used to track bone density changes in pregnant women without posing a risk to the fetus. Studies have shown that REMS can be used to detect conditions such as Pregnancy and Lactation Associated Osteoporosis (PLAO) and transient pregnancy-associated osteoporosis of the hip, which can lead to increased fracture risk.

Chronic Disorders and Secondary Fracture Prevention

In populations with chronic diseases such as diabetes, rheumatoid arthritis, and chronic kidney disease, REMS has demonstrated its utility in accurately assessing bone health and predicting fracture risk. For instance, in a cohort of patients with type 2 diabetes, REMS was able to identify osteoporosis in a higher percentage of individuals compared to DXA, highlighting its potential for earlier intervention.

Secondary Fracture Prevention

The portability of REMS allows for quick assessments of bone health in patients post-fracture, facilitating timely interventions in the management of osteoporosis and fracture prevention. This is particularly useful in hospital settings, emergency departments, and post-operative care, where rapid BMD assessment can guide therapeutic decisions and improve patient outcomes.

Future Directions and Considerations

The future of REMS technology holds exciting potential for further improving osteoporosis diagnosis and management. Ongoing research is focused on enhancing the technology’s precision, expanding its applications to additional skeletal sites, and integrating it with other diagnostic tools like the FRAX® score for more comprehensive fracture risk assessments.

As REMS continues to gain acceptance, it is expected to play an increasing role in osteoporosis management, particularly in settings where traditional DXA may not be available or practical. Its portability, ease of use, and ability to overcome the limitations of DXA make it a valuable tool for personalized bone health management.

Conclusion

REMS represents a significant advancement in the diagnosis and management of osteoporosis, offering a portable, non-ionizing, and highly effective alternative to traditional DXA. With its ability to measure both BMD and bone quality, and its predictive capabilities through the Fragility Score, REMS is poised to become an essential tool in the clinical management of osteoporosis. Its deployment in diverse settings, including primary care, emergency departments, and at home, ensures that it can reach a broader range of patients, particularly those who are underserved by conventional BMD assessment methods.

The growing body of evidence supporting REMS in clinical practice, along with its ability to provide comprehensive bone health assessments, makes it a promising tool for improving patient outcomes in the management of osteoporosis and preventing fragility fractures.